Skip to content

Press

Portfolio-Press Releases
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024 Feb 15, 2024
Portfolio-Press Releases
BioTechnology Innovators Honored in 3rd Annual BioTech Breakthrough Awards Program
November 8, 2023 Nov 8, 2023
Portfolio-Press Releases
Nido Biosciences Presents Clinical Data Supporting the Continued Development of NIDO-361 in SBMA Patients at the 2023 International Kennedy’s Disease Patient Conference
November 5, 2023 Nov 5, 2023
Portfolio-Press Releases
ReCode Therapeutics Announces Closing of Extension to Series B Financing
September 19, 2023 Sep 19, 2023
Portfolio-Press Releases
Recode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
July 10, 2023 Jul 10, 2023
Portfolio-Press Releases
Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
May 16, 2023 May 16, 2023
Portfolio-Press Releases
Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases
May 15, 2023 May 15, 2023
Portfolio-Press Releases
Recode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development
April 17, 2023 Apr 17, 2023
Portfolio-Press Releases
Ensoma Announces Closing of Twelve Bio Acquisition
February 9, 2023 Feb 9, 2023
Portfolio-Press Releases
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
January 5, 2023 Jan 5, 2023